EGFR mutations are common and are seen in 10-15% of North American/European NSCLC, but up to 30-50% of East Asian patients.(ref) They are characteristically seen in pulmonary adenocarcinoma with bronchoalveolar features, particularly in patients without a history of smoking. This evidence concerns the gene EGFR and non-small cell lung carcinoma.